Alzheimer's disease diagnostic criteria: Practical applications

Alzheimer's Research and Therapy

Volumn 4, Issue 4, 2012, Pages

  Cummings, Jeffrey ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; TAU PROTEIN;

ADL DISABILITY; ALZHEIMER DISEASE; COGNITION; DEMENTIA; HUMAN; KNOWLEDGE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CODING; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84865085141     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt138     Document Type: Review

References (32)

1. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
2. Diagnostic and Statistical Manual of Mental Disorders Washington, DC: American Psychiatric Association 4 1990
3. International Classification of Diseases. 10th revision Geneva, Switzerland: World Health Organization 1992
4. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. Beach TG, Monsell SE, Phillips LE, Kukull W, J Neuropathol Exp Neuro 2012 71 266 273 10.1097/NEN.0b013e31824b211b 22437338
5. Cerebrospinal fluid levels of -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O, Arch Gen Psychiatry 2012 69 98 106 10.1001/archgenpsychiatry.2011.155 22213792
6. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM, EMBO Mol Med 2009 1 371 380 10.1002/emmm.200900048 20049742
7. Frequent amyloid deposition without significant cognitive impairment among the elderly. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE, Arch Neurol 2008 65 1509 1517 10.1001/archneur.65.11.1509 19001171
8. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Westman E, Muehlboeck JS, Simmons A, Neuroimage 2012 62 229 238 10.1016/j.neuroimage.2012.04.056 22580170
9. Longitudinal imaging of Alzheimer pathology using [(11)C]PIB, [(18)F]FDDNP and [(18)F]FDG PET. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN, Eur J Nucl Med Mol Imaging 2012 39 990 1000 10.1007/s00259-012-2102-3 22441582
10. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease. Alegret M, Cuberas-Borrás G, Vinyes-Junqué G, Espinosa A, Valero S, Hernández I, Roca I, Ruiz A, Rosende-Roca M, Mauleán A, Becker JT, Castell-Conesa J, Tarraga L, Boada M, J Alzheimers Dis 2012 30 109 120 22406443
11. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2007 6 734 746 Review 10.1016/S1474-4422(07) 70178-3 17616482 (Pubitemid 47058377)
12. Revising the definition of Alzheimer's disease: a new lexicon. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2010 9 1118 1127 10.1016/S1474-4422(10) 70223-4 20934914
13. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P, J Alzheimers Dis 2012 29 319 327 22233766
14. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK, Alzheimer's Disease Neuroimaging Initiative, Neurology 2011 77 1619 1628 10.1212/WNL. 0b013e3182343314 21998317
15. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer's Disease Neuroimaging Initiative, Arch Gen Psychiatry 2011 68 961 969 10.1001/archgenpsychiatry.2011.96 21893661
16. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alzheimers Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003 21514248
17. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH, Alzheimers Dement 2011 7 270 279 10.1016/j.jalz.2011.03.008 21514249
18. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250
19. Mild cognitive impairment: clinical characterization and outcome. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E, Arch Neurol 1999 56 303 308 Erratum in Arch Neurol 1999, 56:760 10.1001/archneur.56.3.303 10190820 (Pubitemid 29120227)
20. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC, Arch Neurol 2006 63 674 681 10.1001/archneur.63.5.674 16682537
21. Outcomes of mild cognitive impairment by definition: a population study. Ganguli M, Snitz BE, Saxton JA, Chang CC, Lee CW, Vander Bilt J, Hughes TF, Loewenstein DA, Unverzagt FW, Petersen RC, Arch Neurol 2011 68 761 767 10.1001/archneurol.2011.101 21670400
22. Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment. Teng E, Becker BW, Woo E, Cummings JL, Lu PH, Dement Geriatr Cogn Disord 2010 30 189 197 10.1159/000313540 20798539
23. Toward a multifactorial model of Alzheimer disease. Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC, Neurobiol Aging 2012 33 2262 2271 10.1016/j.neurobiolaging.2011.11.029 22261556
24. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Morris JC, Arch Neurol 2012 22312163
25. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Katzman R, Arch Neurol 1976 33 217 218 10.1001/archneur.1976. 00500040001001 1259639
26. Global prevalence of dementia: a Delphi consensus study. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease International, Lancet 2005 366 2112 2117 16360788 (Pubitemid 41797645)
27. Addressing the ethical, policy and social challenges of preclinical Alzheimer's disease. Karlawish J, Neurology 2011 77 1487 1493 10.1212/WNL.0b013e318232ac1a 21917767
28. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O, J Alzheimers Dis 2010 21 1119 1128 21504133
29. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebrospinal fluid related biomarkers for drug affecting amyloid burden-regulatory considerations by European Medicines Agence focusing in improving benefit/risks in regulatory trials. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L, European Neuropsychopharm 2011 21 781 788 10.1016/j.euroneuro.2011.08.003 21903360
30. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. Truffinet P, Bordet R, Ménard J, Therapie 2009 64 139 148 10.2515/therapie/2009021 19671425
31. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC, J Nucl Med 2011 52 1210 1217 10.2967/jnumed.111. 089730 21764791
32. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM, Ann Neurol 2007 62 229 234 10.1002/ana.21164 17683091 (Pubitemid 47525398)